Royalty Pharma plc: Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
Barchart on MSN17h
Wall Street Predict 92% Upside for This Dividend Stock: Should You Buy It Now?
Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.